Classical Pathology and Mutational Load of Breast Cancer - Integration of Two Worlds

Overview

Journal J Pathol Clin Res

Specialty Pathology

Date 2016 Aug 9

PMID 27499907

Citations 49

Authors

Jan Budczies

Michael Bockmayr

Carsten Denkert

Frederick Klauschen

Jochen K Lennerz

Balazs Gyorffy

Manfred Dietel

Sibylle Loibl

Wilko Weichert

Albrecht Stenzinger

Affiliations

Soon will be listed here.

Abstract

Breast cancer is a complex molecular disease comprising several biological subtypes. However, daily routine diagnosis is still based on a small set of well-characterized clinico-pathological variables. Here, we try to link the two worlds of surgical pathology and multilayered molecular profiling by analyzing the relationships between clinico-pathological phenotypes and mutational loads of breast cancer. We evaluated the number of mutated genes with somatic non-silent mutations in different subgroups of breast cancer based on clinico-pathological, including immunohistochemical and tumour characteristics. The analysis was performed for a cohort of 687 primary breast cancer patients with mutational profiling, gene expression and clinico-pathological data available from The Cancer Genome Atlas (TCGA) project. The number of mutated genes was strongly positively associated with higher tumour grade (p = 1.4e-14) and with the different immunohistochemical and PAM50 molecular subtypes of breast cancer (p = 1.4e-10 and p = 4.3e-10, respectively). We observed significant associations (|R| > 0.4) between the abundance of mutated genes and expression levels of genes related to proliferation in the overall cohort and hormone receptor positive cohort, including the Recurrence Score gene signature (e.g., MYBL2 and BIRC5). Specific mutated genes (TP53, NCOR1, NF1, PTPRD and RB1) were highly significantly associated with high loads of mutated genes. Multivariate analysis for overall survival (OS) revealed a worse survival for patients with high numbers of mutated genes (hazard ratio = 4.6, 95% CI: 1.0 - 20.0, p = 0.044). Here, we report a strong association of the number of mutated genes with immunohistochemical and PAM50 subtypes and tumour grade in breast cancer. We provide evidence that specific levels of the mutational load underlie different morphological and biological phenotypes, which collectively constitute the current basis of pathological diagnosis. Our study is a step towards genomics-informed breast pathology and will provide a basis for future studies in this field bridging the gap between morphology, tumour biology and medical oncology.

Citing Articles

Prognostic and Therapeutic Implications of Cell Division Cycle 20 Homolog in Breast Cancer.

Messeha S, Zarmouh N, Maku H, Gendy S, Yedjou C, Elhag R Cancers (Basel). 2024; 16(14.

PMID: 39061186 PMC: 11274456. DOI: 10.3390/cancers16142546.

Visual Intratumor Heterogeneity and Breast Tumor Progression.

Li Y, Van Alsten S, Lee D, Kim T, Calhoun B, Perou C Cancers (Basel). 2024; 16(13).

PMID: 39001357 PMC: 11240824. DOI: 10.3390/cancers16132294.

Novel Dual-Mode NIR-II/MRI Nanoprobe Targeting PD-L1 Accurately Evaluates the Efficacy of Immunotherapy for Triple-Negative Breast Cancer.

Liu W, Zhang Y, Luo X, Zhu Y, Song L, Ming Z Int J Nanomedicine. 2023; 18:5141-5157.

PMID: 37705867 PMC: 10497065. DOI: 10.2147/IJN.S417944.

Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.

Fabi A, Carbognin L, Botticelli A, Paris I, Fuso P, Savastano M NPJ Breast Cancer. 2023; 9(1):73.

PMID: 37684252 PMC: 10491680. DOI: 10.1038/s41523-023-00579-2.

Combining histological grade, TILs, and the PD-1/PD-L1 pathway to identify immunogenic tumors and de-escalate radiotherapy in early breast cancer: a secondary analysis of a randomized clinical trial.

Stenmark Tullberg A, Sjostrom M, Tran L, Nimeus E, Killander F, Kovacs A J Immunother Cancer. 2023; 11(5).

PMID: 37208129 PMC: 10201214. DOI: 10.1136/jitc-2022-006618.

References

Eirew P, Steif A, Khattra J, Ha G, Yap D, Farahani H . Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature. 2014; 518(7539):422-6. PMC: 4864027. DOI: 10.1038/nature13952. View

Petridis C, Shinomiya I, Kohut K, Gorman P, Caneppele M, Shah V . Germline CDH1 mutations in bilateral lobular carcinoma in situ. Br J Cancer. 2013; 110(4):1053-7. PMC: 3929874. DOI: 10.1038/bjc.2013.792. View

Budczies J, von Winterfeld M, Klauschen F, Bockmayr M, Lennerz J, Denkert C . The landscape of metastatic progression patterns across major human cancers. Oncotarget. 2014; 6(1):570-83. PMC: 4381616. DOI: 10.18632/oncotarget.2677. View

Reis-Filho J, Pusztai L . Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet. 2011; 378(9805):1812-23. DOI: 10.1016/S0140-6736(11)61539-0. View

Rakha E, Ellis I . Modern classification of breast cancer: should we stick with morphology or convert to molecular profile characteristics. Adv Anat Pathol. 2011; 18(4):255-67. DOI: 10.1097/PAP.0b013e318220f5d1. View

Almendro V, Kim H, Cheng Y, Gonen M, Itzkovitz S, Argani P . Genetic and phenotypic diversity in breast tumor metastases. Cancer Res. 2014; 74(5):1338-48. PMC: 3963810. DOI: 10.1158/0008-5472.CAN-13-2357-T. View

Baccelli I, Stenzinger A, Vogel V, Pfitzner B, Klein C, Wallwiener M . Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patients. Oncotarget. 2014; 5(18):8147-60. PMC: 4226673. DOI: 10.18632/oncotarget.2385. View

Wang Y, Waters J, Leung M, Unruh A, Roh W, Shi X . Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature. 2014; 512(7513):155-60. PMC: 4158312. DOI: 10.1038/nature13600. View

Cornejo K, Kandil D, Khan A, Cosar E . Theranostic and molecular classification of breast cancer. Arch Pathol Lab Med. 2014; 138(1):44-56. DOI: 10.5858/arpa.2012-0442-RA. View

10.

Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C . Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. DOI: 10.1038/35021093. View

11.

Mittendorf E, Jeruss J, Tucker S, Kolli A, Newman L, Gonzalez-Angulo A . Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol. 2011; 29(15):1956-62. PMC: 3107758. DOI: 10.1200/JCO.2010.31.8469. View

12.

Garza R, Hudson 3rd R, McMahan C, Walter C, Vogel K . A mild mutator phenotype arises in a mouse model for malignancies associated with neurofibromatosis type 1. Mutat Res. 2007; 615(1-2):98-110. DOI: 10.1016/j.mrfmmm.2006.11.031. View

13.

Nik-Zainal S, Van Loo P, Wedge D, Alexandrov L, Greenman C, Lau K . The life history of 21 breast cancers. Cell. 2012; 149(5):994-1007. PMC: 3428864. DOI: 10.1016/j.cell.2012.04.023. View

14.

Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B . Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008; 10(4):R65. PMC: 2575538. DOI: 10.1186/bcr2124. View

15.

Sorlie T, Tibshirani R, Parker J, Hastie T, Marron J, Nobel A . Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003; 100(14):8418-23. PMC: 166244. DOI: 10.1073/pnas.0932692100. View

16.

Goldhirsch A, Wood W, Coates A, Gelber R, Thurlimann B, Senn H . Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011; 22(8):1736-47. PMC: 3144634. DOI: 10.1093/annonc/mdr304. View

17.

Elston C, Ellis I . Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991; 19(5):403-10. DOI: 10.1111/j.1365-2559.1991.tb00229.x. View

18.

Viale G . The current state of breast cancer classification. Ann Oncol. 2012; 23 Suppl 10:x207-10. DOI: 10.1093/annonc/mds326. View

19.

Wallace M, Pfefferle A, Shen L, McNairn A, Cerami E, Fallon B . Comparative oncogenomics implicates the neurofibromin 1 gene (NF1) as a breast cancer driver. Genetics. 2012; 192(2):385-96. PMC: 3454871. DOI: 10.1534/genetics.112.142802. View

20.

Burrell R, McGranahan N, Bartek J, Swanton C . The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 2013; 501(7467):338-45. DOI: 10.1038/nature12625. View